Vericel Awarded $197M BARDA Contract for Procurement and Advanced Development

The contract will support Vericel's cell therapy manufacturing and clinical trials.

Apr. 2, 2026 at 9:17pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a group of sleek, geometric medical devices and laboratory equipment arranged in an elegant, minimalist composition on a stark white background, symbolizing the advanced science and technology behind Vericel's cell therapy innovations.Vericel's BARDA contract will fund the advanced development and manufacturing of its innovative cell therapy products.Cambridge Today

Vericel Corporation, a biopharmaceutical company focused on developing advanced cell therapies, has been awarded a contract valued at up to $197 million from the Biomedical Advanced Research and Development Authority (BARDA). The contract will support Vericel's procurement of raw materials and advanced development of its cell therapy products.

Why it matters

This significant government contract validates Vericel's expertise in cell therapy manufacturing and development, and provides critical funding to advance its pipeline of regenerative medicine products. The award highlights BARDA's confidence in Vericel's capabilities to deliver innovative solutions that could benefit public health emergencies.

The details

The BARDA contract will support Vericel's procurement of raw materials needed for cell therapy production, as well as advanced development activities for its investigational products. This includes funding for clinical trials and regulatory submissions to the FDA. Vericel specializes in autologous cell therapies, which use a patient's own cells to create personalized treatments.

  • Vericel was awarded the BARDA contract on April 2, 2026.

The players

Vericel Corporation

A biopharmaceutical company focused on developing advanced cell therapy products.

Biomedical Advanced Research and Development Authority (BARDA)

A division of the U.S. Department of Health and Human Services that supports the advanced research and development of medical countermeasures.

Got photos? Submit your photos here. ›

What’s next

Vericel plans to use the BARDA funding to accelerate the clinical development and manufacturing scale-up of its cell therapy pipeline, with the goal of bringing these innovative regenerative medicine products to patients in need.

The takeaway

This substantial government contract demonstrates Vericel's leadership in cell therapy development and manufacturing, and provides the resources needed to advance its promising pipeline of regenerative medicine solutions that could have a significant impact on public health.